NasdaqGM - Delayed Quote USD

Arcturus Therapeutics Holdings Inc. (ARCT)

12.73

+0.91

+(7.70%)

At close: May 29 at 4:00:01 PM EDT

12.80

+0.07

+(0.55%)

After hours: May 29 at 6:33:43 PM EDT

Key Events

Loading Chart for ARCT

Previous Close 11.82
Open 11.87
Bid 9.20 x 200
Ask 15.02 x 200
Day's Range 11.51 - 12.80
52 Week Range 8.04 - 45.00
Volume 432,244
Avg. Volume 426,122
Market Cap (intraday) 345.245M
Beta (5Y Monthly) 2.37
PE Ratio (TTM) --
EPS (TTM) -2.52
Earnings Date Aug 4, 2025 - Aug 8, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 66.80

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

174

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ARCT

24.99%

S&P 500 (^GSPC)

0.52%

1-Year Return

ARCT

65.33%

S&P 500 (^GSPC)

12.25%

3-Year Return

ARCT

39.03%

S&P 500 (^GSPC)

42.18%

5-Year Return

ARCT

67.31%

S&P 500 (^GSPC)

94.20%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Arcturus Therapeutics Holdings Inc.

12.73

+7.70%

Mkt Cap 345.245M

Industry Biotechnology

Editas Medicine, Inc.

1.8300

-2.14%

Mkt Cap 156.543M

Industry Biotechnology

Sage Therapeutics, Inc.

6.52

+0.62%

Mkt Cap 408.287M

Industry Biotechnology

3.2200

+5.57%

Mkt Cap 4.258M

Industry Biotechnology

Ionis Pharmaceuticals, Inc.

33.46

+3.18%

Mkt Cap 5.325B

Industry Biotechnology

4.6300

+4.28%

Mkt Cap 1.042B

Industry Biotechnology

Vir Biotechnology, Inc.

5.19

+9.03%

Mkt Cap 717.455M

Industry Biotechnology

Vera Therapeutics, Inc.

19.93

+5.62%

Mkt Cap 1.271B

Industry Biotechnology

SpringWorks Therapeutics, Inc.

46.68

0.00%

Mkt Cap 3.517B

Industry Biotechnology

Arcutis Biotherapeutics, Inc.

13.67

+0.66%

Mkt Cap 1.629B

Industry Biotechnology

ADC Therapeutics SA

2.7700

+4.53%

Mkt Cap 274.724M

Industry Biotechnology

Valuation Measures

    Annual 

As of 5/29/2025

Market Cap

345.25M
Enterprise Value

170.96M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

2.62
Price/Book (mrq)

1.48
Enterprise Value/Revenue

1.30
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-47.47%
Return on Assets (ttm)

-13.67%
Return on Equity (ttm)

-27.40%
Revenue (ttm)

143.68M
Net Income Avi to Common (ttm)

-68.2M
Diluted EPS (ttm)

-2.52

Balance Sheet and Cash Flow

Total Cash (mrq)

216.95M
Total Debt/Equity (mrq)

18.25%
Levered Free Cash Flow (ttm)

-53.72M

TWST Twist Bioscience Corporation

28.89

+1.98%

CDNA CareDx, Inc

16.56

-5.69%

PSNL Personalis, Inc.

4.5900

-2.34%

IOVA Iovance Biotherapeutics, Inc.

1.8300

+4.57%

PACB Pacific Biosciences of California, Inc.

1.0400

-5.45%